To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Isolated limb perfusion a… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Isolated limb perfusion as a treatment option for rare types of tumours

Journal article
Authors Valerio Belgrano
Ilan Ben-Shabat
Peter Bergh
Roger Olofsson Bagge
Published in International Journal of Hyperthermia
Volume 32
Issue 6
Pages 595-599
ISSN 0265-6736
Publication year 2016
Published at Institute of Clinical Sciences, Department of Surgery
Institute of Clinical Sciences, Department of Orthopaedics
Pages 595-599
Language en
Keywords Advanced status, isolated limb perfusion, local control, rare tumours, necrosis-factor-alpha, soft-tissue sarcomas, t-cell lymphoma, malignant-melanoma, regional perfusion, complete remission, tnf-alpha, melphalan, extremities, carcinoma, Oncology, Radiology, Nuclear Medicine & Medical Imaging
Subject categories Clinical Medicine


Background: Isolated limb perfusion (ILP) is an established and effective treatment for advanced melanoma and soft tissue sarcomas of the extremities with a high overall response rate. The aim of this study was to describe our experience of ILP for more rare types of tumours. Methods: Patients with Merkel cell carcinoma (MCC) (n = 4), squamous cell carcinoma (SCC) (n = 2), B-cell lymphoma (n = 1), desmoid tumours (n = 3), pigmented villonodular synovitis (PVNS) (n = 1) and giant cell tumour (n = 1) were treated with ILP and analysed retrospectively. Results: The four patients with in-transit MCC had three complete responses (CR) and one partial response (PR); the two patients with SCC had one CR and one stable disease (SD); the patients with desmoid tumours had two PR and one SD. A CR was also observed for the patient with a giant cell tumour, but the patient with PVNS had a SD. The patient with cutaneous metastases of B-cell lymphoma showed a CR, however with rapid systemic progression. Local toxicity according to Wieberdink was grade II in 10 patients (83%) and grade III in two patients (17%). Conclusions: These results show that ILP can be used as a treatment option also for more rare disease entities when other treatments have failed.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?